Recruiting
Early Phase 1

Monoaminergic Drive

Sponsor:

Northwestern University

Code:

NCT06666673

Conditions

Stroke

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Tizanidine

Placebo

Study Details

Brief summary:

This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.

Conditions

Stroke

Study ID

NCT06666673

Start date

Aug 23, 2024

Status verified date

Aug, 2026

Completion date

Jul 31, 2029

Anticipated

Primary completion date

Jun 30, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment
  • Age between 18-80
  • Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 10-50/66)
  • Ability to communicate, understand, and provide informed consent
  • Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate active elbow extension
  • MRI compatible
  • Intact skin on the hemiparetic arm
  • Ability to sit for three hours.

Exclusion Criteria:

  • Motor or sensory impairment in the non-affected limb (FMA<66, filament >3.6)
  • Any brainstem and/or cerebellar lesion
  • untreated cardiovascular disease
  • History of neurologic disorder other than stroke that affects the arms
  • Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale
  • Current use of a pacemaker
  • History of seizure
  • Chemo denervation: botulinum toxin injection to any portion of the paretic upper extremity within the last 6 months, or phenol/alcohol injections <12 months before participation
  • Flexion contractures larger than 30 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) after stretching for 15 minutes
  • Current participation in any experimental rehabilitation or drug studies
  • Individuals with any known contraindications to Tizanidine or currently taking Tizanidine; - concurrent use of medications known to suppress central nervous system activity
  • pregnant women or women who are nursing.

Additionally, each participant will be asked to provide a list of their current medications and a medical screening questionnaire will be sent to their primary physician. Each participant's list of medications will be reviewed for possible interactions with the study drugs and, at the study physician's advice, will be excluded from the study or asked to withhold medications when applicable. A full list of potential drug interactions can be seen in "Medication Interactions", but concisely includes the following: medications with dopaminergic, serotonergic, or noradrenergic actions; central nervous system (CNS) depressants; antihypertensive/ antiarrhythmic agents; and hormonal medications/contraceptives.

Study Design

Enrollment

64 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

placebo comparator: Placebo

One lactose pill will be administered as a control.

active comparator: Drug Probe

4 mg Tizanidine

Interventions

Tizanidine

Tizanidine (TIZ) (Zanaflex®) is a centrally acting noradrenergic α-2 agonist and a ligand of I3 (non-I1/I2) imidazoline receptors. It is currently indicated for the management of spasticity.

Placebo

Administered as control

Primary outcome measure

  • Brace Height [ Time Frame: Before and 1.5 hours after administration of TIZ ]
  • Cortico-muscular-coherence in beta band [ Time Frame: Before and 1.5 hours after administration of TIZ ]
  • Difference in reaching distance under shoulder abduction load [ Time Frame: Before and 1.5 hours after administration of TIZ ]
  • Reflexive electromyograph activity prior to movement [ Time Frame: Before and 1.5 hours after administration of TIZ ]

Central Contacts and Locations

Central contacts

Locations

Northwestern University, Dept. of PTHMS 645 N Michigan Ave, Suite 1100

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Principal Investigator:

Julius Dewald, DPT, PhD

More Information

Sponsor

Northwestern University

Last update posted

Aug 18, 2026

Last verified

Aug, 2026

Keywords

  • Neurotransmitters
  • flexion synergy
  • brain plasticity
  • tizanidine
  • stroke
  • motor control
  • spasticity

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Northwestern University on 2026-08-18.